Cas:128879-80-1 2-aminophthalylhydrazido-n-acetyl-b-d-glucosaminide manufacturer & supplier

We serve Chemical Name:2-aminophthalylhydrazido-n-acetyl-b-d-glucosaminide CAS:128879-80-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

2-aminophthalylhydrazido-n-acetyl-b-d-glucosaminide

Chemical Name:2-aminophthalylhydrazido-n-acetyl-b-d-glucosaminide
CAS.NO:128879-80-1
Synonyms:2-Aminophthalylhydrazido-N-acetyl–D-glucosaminide;O-AMINOPHTHALYLHYDRAZIDO-N-ACETYL-B-D-GL UCOSAMINID;O-aminophthalylhydrazido-N-acetyl-B-D-*glucosamin;LUM-NAG
Molecular Formula:C16H20N4O7
Molecular Weight:380.35300
HS Code:

Physical and Chemical Properties:
Melting point:178-180ºC
Boiling point:N/A
Density:1.77g/cm3
Index of Refraction:1.743
PSA:180.02000
Exact Mass:380.13300
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 2-Aminophthalylhydrazido-N-acetyl–D-glucosaminide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,LUM-NAG physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,O-aminophthalylhydrazido-N-acetyl-B-D-*glucosamin Use and application,O-AMINOPHTHALYLHYDRAZIDO-N-ACETYL-B-D-GL UCOSAMINID technical grade,usp/ep/jp grade.


Related News: The therapy is designed to treat ADA-SCID, a genetic condition in which children are born without a properly functioning immune system. 2-(2,2,2-trichloro-ethyl)-glutaric acid manufacturers Flexibility in a CDMO is the key to ensure speed of tech-transfer which is a true litmus test for CDMOs which can help a company chose between competing analytical strategies, manufacturing technology and knowledge for improving productivity. (E)-2-(N-(3-(2-(4-cyclobutylthiazol-2-yl)vinyl)benzyl)-N-(3-((4-fluorophenyl)sulfonyl)propyl)sulfamoyl)benzoic acid suppliers Soliris would need a “substantial discount” to reach a more appropriate price, according to its report. Using the widely leveraged measure for disease burden known as quality-adjusted life year (QALY), ICER calculated a range of $6,900 to achieve $50,000 per QALY to $25,700 to hit $200,000 per QALY. 6-bromo-N-(1,2-dihydroacenaphthylen-5-yl)phenanthridine-5(6H)-carboximidamide vendor & factory.